Structural variation in the glycogen synthase kinase 3β and brain‐derived neurotrophic factor genes in Japanese patients with bipolar disorders

Abstract Background Lithium is the first‐line drug for the treatment of bipolar disorders (BDs); however, not all patients responded. Glycogen synthase kinase (GSK) 3β and brain‐derived neurotrophic factor (BDNF) play a role in the therapeutic action of lithium. Since structural variations were repo...

Disgrifiad llawn

Manylion Llyfryddiaeth

Prif Awduron:	Yosuke Suga, Keiichiro Yoshimoto, Shusuke Numata, Shinji Shimodera, Shogo Takamura, Naoto Kamimura, Ken Sawada, Hiromitsu Kazui, Tetsuro Ohmori, Shigeru Morinobu
Fformat:	Artigo
Iaith:	Inglês
Cyhoeddwyd:	Wiley 2020-03-01
Cyfres:	Neuropsychopharmacology Reports
Pynciau:	bipolar disorder brain‐derived neurotrophic factor copy number variation glycogen synthase kinase 3® lithium
Mynediad Ar-lein:	https://doi.org/10.1002/npr2.12083
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!